Kidney transplantation leads to an increased risk of cancer. Melanoma is one of the most frequent neoplasms in kidney transplant recipients. Transplanted patients were excluded from trials with checkpoint inhibitors in melanoma. The authors performed a systematic review regarding the use of anti-PD1 and anti-CTLA4 agents in renal transplanted patients with melanoma. Thirty-four cases were included (24 progressive disease, eight partial responses and one stable disease) but no complete response were reported. Fourteen graft rejections were observed, especially with anti-PD1 agent. The median time from the start of immune-checkpoint inhibitor and rejection was 21 days. Response rate was similar between patients with rejection and patients without rejection. The benefit of immune-checkpoint inhibitors versus the risk of allograft rejection should be carefully weighted for each patient. A multidisciplinary approach should be considered to discuss the most appropriate treatment for every case, given the aggressiveness of melanoma in these subsets of patients.

Rossi, E., Schinzari, G., Maiorano, B. A., Esposito, I., Acampora, A., Romagnoli, J., Stefani, A. D., Regno, L. D., Lancellotta, V., Fionda, B., Tagliaferri, L., Peris, K., Tortora, G., Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: A systematic review, <<IMMUNOTHERAPY>>, 2022; 14 (1): 65-76. [doi:10.2217/imt-2021-0195] [http://hdl.handle.net/10807/197974]

Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: A systematic review

Schinzari, G.;Maiorano, B. A.;Acampora, A.;Romagnoli, J.;Tagliaferri, L.;Peris, K.;Tortora, G.
2022

Abstract

Kidney transplantation leads to an increased risk of cancer. Melanoma is one of the most frequent neoplasms in kidney transplant recipients. Transplanted patients were excluded from trials with checkpoint inhibitors in melanoma. The authors performed a systematic review regarding the use of anti-PD1 and anti-CTLA4 agents in renal transplanted patients with melanoma. Thirty-four cases were included (24 progressive disease, eight partial responses and one stable disease) but no complete response were reported. Fourteen graft rejections were observed, especially with anti-PD1 agent. The median time from the start of immune-checkpoint inhibitor and rejection was 21 days. Response rate was similar between patients with rejection and patients without rejection. The benefit of immune-checkpoint inhibitors versus the risk of allograft rejection should be carefully weighted for each patient. A multidisciplinary approach should be considered to discuss the most appropriate treatment for every case, given the aggressiveness of melanoma in these subsets of patients.
Inglese
Rossi, E., Schinzari, G., Maiorano, B. A., Esposito, I., Acampora, A., Romagnoli, J., Stefani, A. D., Regno, L. D., Lancellotta, V., Fionda, B., Tagliaferri, L., Peris, K., Tortora, G., Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: A systematic review, <<IMMUNOTHERAPY>>, 2022; 14 (1): 65-76. [doi:10.2217/imt-2021-0195] [http://hdl.handle.net/10807/197974]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/197974
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact